Biotech Values

[mcbio]

PGNX likely needs to raise some cash IMO. No approval cost them a $40M milestone and now they need more clinical data. It also delays oral Relistor filing. I will wait for an offering.

I tend to agree though I do think their anti-PSMA drug for prostate cancer may generate interest down the road. Seems to be showing early signs of an effect. Not sure I'll get back in the name though. Relistor doesn't seem to be in good shape now, pending further clarity, and that was a key drug for PGNX.